SUPN acquires SAGE for $8.50/sh +CVR—a 27% premium to Friday’s close (excluding the CVR): https://www.globenewswire.com/news-release/2025/06/16/3099695/19871/en/Supernus-Pharmaceuticals-to-Acquire-Sage-Therapeutics-Strengthening-its-Neuropsychiatry-Product-Portfolio.html The nominal deal value, excluding the CVR, is $561M.